Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

JAMA Oncology
Nancy Y YuLinda Sofie Lindström

Abstract

Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood. To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated. Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012, were obtained from the Swedish National registers. Data analysis for the secondary analysis was conducted in 2017 and 2018. Patients were randomized to receive at least 2 years of tamoxifen therapy or no endocrine therapy; patients without recurrence who reconsented were further randomized to 3 additional years of tamoxifen therapy or no endocrine therapy. Distant recurrence-free interval (DRFI)...Continue Reading

References

Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·C M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James D BrentonCarlos Caldas
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clifford A HudisJo Anne Zujewski
Sep 4, 2008·Acta Oncologica·Lotti BarlowMats Talbäck
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aleix PratCharles M Perou
Sep 4, 2013·Breast Care·Nadia HarbeckMichael Gnant
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felipe AdesMartine Piccart
Jan 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco ColleoniAron Goldhirsch
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Jan 24, 2018·Journal of the National Cancer Institute·Linda S LindströmUNKNOWN STO Trialists Group

❮ Previous
Next ❯

Citations

Dec 13, 2019·JAMA Oncology·Steven A NarodVictoria Sopik
Aug 28, 2020·International Journal of Molecular Sciences·Tung-Yi LinTai-Long Pan
Nov 9, 2021·Journal of the National Cancer Institute·Rikke Nørgaard PedersenDeirdre Cronin-Fenton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.